Collision Tumor in the Stomach: Tubular Gastric Adenocarcinoma With Metastatic Adrenocortical Carcinoma-A Rare Encounter on an Endoscopic Biopsy.

Int J Surg PatholMar 31, 2026 (epub)

Palak Arora, Md Ali Osama, Rajni Yadav et al.

✦ AI-curated · Sources linked

Case in brief

A gastric lesion was found to contain two distinct malignancies: primary tubular gastric adenocarcinoma and metastatic adrenocortical carcinoma. The tumors met at an abrupt interface without transitional morphology, supporting a collision tumor rather than a single neoplasm with mixed differentiation. The report emphasizes that endoscopic, histopathological, and immunohistochemical assessment was needed to distinguish the two components. Recognizing the metastatic component was clinically important because it affects staging, management, and prognosis.

What made this case unusual

The collision involved a primary gastric carcinoma and metastatic adrenocortical carcinoma. Gastric metastasis from adrenocortical carcinoma is very rare, and the report states that this combination had not previously been described.

Diagnostic / clinical pearl

When a gastric lesion has discordant morphologic features, consider the possibility of a collision tumor and use histopathology and immunohistochemistry to identify distinct primary and metastatic components.

Why it matters

Correctly identifying a metastatic component, rather than classifying the lesion as solely a primary gastric cancer, can alter staging, management, and prognosis.

Source

Published in Int J Surg Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.